-
Iptacopan (CAS: 1644670-37-0)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Suzetrigine paroxysmal nocturnal hemoglobinuria（PNH）
IGA nephropathyNovartis Jul.14,2034 -
Suzetrigine (CAS: 2649467-58-1)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Suzetrigine Analgesic Vertex Pharmaceuticals Dec.4,2040 -
Orforglipron (CAS: 2212020-52-3)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Orforglipron Type 2 Diabetes Eli Lilly and Company Sep.26,2037 -
Osimertinib (CAS: 1421373-65-0)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Osimertinib NSCLC AstraZeneca Aug.8,2032 -
Alectinib (CAS: 1256580-46-7)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Alectinib NSCLC Roche Pharma AG Jun. 9,2030 -
Zanubrutinib (CAS: 1691249-45-2)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Zanubrutinib MCL/CLL/SLL/WM BeiGene Apr.2034 -
Dabrafenib (CAS: 1195765-45-7)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Dabrafenib Melanoma Novartis（GSK R&D） Jul.20, 2030 -
Aprocitentan (CAS: 1103522-45-7)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Aprocitentan hypertension Idorsia Pharmaceuticals Deutschland GmbH Sep. 21.2034 -
Etrasimod (CAS: 1206123-37-6)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Etrasimod Ulceratuve Colitis(UC) Arena(Pfizer) Mar.05,2030 -
Tirzepatide (CAS: 2023788-19-2)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Tirzepatide Type 2 diabetes, lose weight Eli Lilly Jan.05,2036 -
Semaglutide (CAS: 910463-68-2)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Semaglutide Type2 diabetes,lose weight Novo Nordisk Dec.05,2031 -
Oteseconazole (CAS: 1340593-59-0)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Oteseconazole Reduce the incidence rate ofrecurrent vulvovaginal candidiasis MycoviaPharmaceuticals Apr.22,2031